Suppr超能文献

前列腺癌从格里森 3 级到 4 级的克隆进展。

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

机构信息

Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

出版信息

Cancer Res. 2013 Feb 1;73(3):1050-5. doi: 10.1158/0008-5472.CAN-12-2799. Epub 2012 Nov 30.

Abstract

Low-grade prostate cancers (Gleason pattern 3, G3) detected on needle biopsies are generally viewed as indolent and suitable for conservative management with only interval repeat biopsies to monitor by watchful waiting. Higher grade tumors eventually emerge in 20% to 30% of these cases, but this process may only reflect incomplete sampling on the initial biopsy, such that it remains unknown whether G3 tumors generally progress to higher grades. In this study, we examined a series of adjacent G3 and Gleason pattern 4 (G4) tumors in radical prostatectomy specimens and found that all were concordant for the TMPRSS2:ERG gene fusion. Using hybrid-capture and deep sequencing in four fusion-positive cases, we found that adjacent laser-capture microdissected G3 and G4 tumors had identical TMPRSS2:ERG fusion breakpoints, confirming their clonal origin. Two of these G3 tumors had deletion of a single PTEN gene that was also deleted in the adjacent G4, while the G4 tumors in two cases had additional PTEN losses. These findings establish that a subset of G3 tumors progress to G4 or emerge from a common precursor. Further, they show that G3 tumors that progress to G4 may have molecular features distinguishing them from G3 tumors that do not progress. Thus, determining the spectrum of these genetic or epigenetic features may allow for the identification of G3 tumors on needle biopsies that are truly indolent versus those that have the potential to progress or that may already be associated with a G4 tumor that was not sampled at the initial biopsy, therefore, requiring more aggressive surveillance or intervention.

摘要

低级别前列腺癌(Gleason 模式 3,G3)在针吸活检中被发现时通常被认为是惰性的,适合采用保守管理,仅通过间隔重复活检进行监测。在这些病例中,大约 20%到 30%的病例最终会出现更高等级的肿瘤,但这一过程可能只是反映了初始活检的不完全取样,因此尚不清楚 G3 肿瘤是否普遍进展为更高等级。在这项研究中,我们检查了一系列根治性前列腺切除术标本中的相邻 G3 和 Gleason 模式 4(G4)肿瘤,发现所有肿瘤的 TMPRSS2:ERG 基因融合均一致。在四个融合阳性病例中使用杂交捕获和深度测序,我们发现相邻的激光捕获微切割 G3 和 G4 肿瘤具有相同的 TMPRSS2:ERG 融合断点,证实了它们的克隆起源。这两个 G3 肿瘤中有一个 PTEN 基因缺失,而相邻的 G4 肿瘤也缺失了该基因,而另外两个病例中的 G4 肿瘤则有额外的 PTEN 缺失。这些发现确立了一部分 G3 肿瘤会进展为 G4 或起源于共同的前体。此外,它们表明进展为 G4 的 G3 肿瘤可能具有与其不进展的 G3 肿瘤区分开来的分子特征。因此,确定这些遗传或表观遗传特征的范围可能有助于在针吸活检中识别真正惰性的 G3 肿瘤与可能进展或可能已经与初始活检未取样的 G4 肿瘤相关的 G3 肿瘤,因此需要更积极的监测或干预。

相似文献

1
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
Cancer Res. 2013 Feb 1;73(3):1050-5. doi: 10.1158/0008-5472.CAN-12-2799. Epub 2012 Nov 30.
2
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Mod Pathol. 2013 Mar;26(3):435-47. doi: 10.1038/modpathol.2012.162. Epub 2012 Sep 28.
5
Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Mod Pathol. 2016 Feb;29(2):143-56. doi: 10.1038/modpathol.2015.136. Epub 2015 Nov 27.
8
Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.
Clin Cancer Res. 2017 Jul 15;23(14):3823-3833. doi: 10.1158/1078-0432.CCR-16-2414. Epub 2017 Jan 24.
10
Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
Prostate. 2019 Nov;79(15):1777-1788. doi: 10.1002/pros.23903. Epub 2019 Sep 10.

引用本文的文献

1
Digital spatial profiling identifies phospho-JNK as a biomarker for early risk stratification of aggressive prostate cancer.
Front Oncol. 2025 Jun 5;15:1572299. doi: 10.3389/fonc.2025.1572299. eCollection 2025.
3
Activin B and Activin C Have Opposing Effects on Prostate Cancer Progression and Cell Growth.
Cancers (Basel). 2022 Dec 27;15(1):147. doi: 10.3390/cancers15010147.
4
Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason Scores 3+5=8 and 5+3=8.
Hum Pathol. 2022 Dec;130:18-24. doi: 10.1016/j.humpath.2022.10.010. Epub 2022 Oct 26.
5
The importance of personalized medicine in urological cancers.
J Diabetes Metab Disord. 2021 Jun 29;21(1):841-852. doi: 10.1007/s40200-021-00824-0. eCollection 2022 Jun.
7
Understanding and targeting prostate cancer cell heterogeneity and plasticity.
Semin Cancer Biol. 2022 Jul;82:68-93. doi: 10.1016/j.semcancer.2021.11.001. Epub 2021 Nov 26.
8
Comparison of approaches to transcriptomic analysis in multi-sampled tumors.
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab337.
9
PTEN expression and morphological patterns in prostatic adenocarcinoma.
Histopathology. 2021 Dec;79(6):1061-1071. doi: 10.1111/his.14531. Epub 2021 Sep 12.

本文引用的文献

1
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Clin Cancer Res. 2011 Oct 15;17(20):6563-73. doi: 10.1158/1078-0432.CCR-11-1244. Epub 2011 Aug 30.
2
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.
J Clin Oncol. 2011 Jul 10;29(20):2795-800. doi: 10.1200/JCO.2010.33.0134. Epub 2011 May 31.
3
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.
4
5
Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.
6
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.
Nat Genet. 2010 Aug;42(8):668-75. doi: 10.1038/ng.613. Epub 2010 Jul 4.
7
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
J Clin Oncol. 2010 Jan 1;28(1):126-31. doi: 10.1200/JCO.2009.24.2180. Epub 2009 Nov 16.
8
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927. Epub 2009 Jul 7.
9
Molecular analysis of multifocal prostate cancer by comparative genomic hybridization.
Prostate. 2008 Dec 1;68(16):1715-24. doi: 10.1002/pros.20832.
10
Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.
J Urol. 2008 Mar;179(3):901-4; discussion 904-5. doi: 10.1016/j.juro.2007.10.062. Epub 2008 Jan 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验